AIDS Therapies (ICAAC Conference News)

Triple NRTI Regimen Data Presented

Published in AIDS Weekly, October 18th, 1999

Forty-eight week data from a study comparing the triple nucleoside reverse transcriptase inhibitor (NRTI) regimen of Ziagen (abacavir sulfate)+Combivir (lamivudine/zidovudine) to treatment with Crixivan (indinavir; Merck) in combination with Combivir were presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in San Francisco, California.

Ziagen currently is approved for use in adults and children in combination with other antiretroviral agents to treat HIV-1 infection. This indication is based on analyses of surrogate markers in controlled studies of up to 24 weeks in duration. Until now, no results from controlled trials...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry